← All trials
NCT04898374
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2021
- Primary completion
- Apr 30, 2025
- Completion date
- Apr 30, 2026
- First posted
- May 24, 2021
- Last posted
- May 24, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kuwait Cancer Control CenterLead sponsor
- Kuwait Cancer Control CenterReponsible party - principal investigator
- Kuwait Cancer Control CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.